With Biogen’s Aducanumab approval dramatically overhauling the regulatory landscape for neurodegenerative disease, the beta amyloid revival is in full swing with investment pouring in across multiple neurodegenerative diseases. With this, biopharma across the globe are racing to harness the exhilarating momentum of the past year and turbocharge their neurodegenerative disease drug development in 2022 and beyond.
From leveraging data from clinical samples to catalyze the next generation of therapies against Alzheimer’s and Parkinson’s disease, learning how to justify investment in rare neurodegenerative diseases, through to taking a multi-omic approach to target discovery, the 10th Neurodegenerative Drug Development Summit will siphon critical insights from Biogen, AbbVie, Roche, Takeda, Novartis and more to help you accelerate therapeutic development through to approval for NDD patients around the world.
Join us to witness this neuroscience renaissance head on and meet with the biggest neurodegenerative KOL’s across this exceedingly challenging and exciting field, as we fight to unravel the complexities of neurodegenerative drug development. Join 200+ neurodegenerative drug development experts to learn from those revolutionising this space into 2022 and beyond.
